Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 17/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 11/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699229 | 0.89 | CTSS (0.45) | ALDH1A1 | |
| SCHEMBL6062378 | 0.84 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL6062452 | 0.77 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL6061707 | 0.75 | CTSS (0.44) | — | |
| SCHEMBL6061704 | 0.75 | CTSS (0.44) | — | |
| SCHEMBL6062653 | 0.74 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL6062001 | 0.74 | CTSK (0.41) | ALDH1A1 | |
| SCHEMBL6062945 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL6062997 | 0.72 | CAPN1 (0.47) | ALDH1A1 | |
| SCHEMBL6695177 | 0.72 | MAP3K7 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | FAAH 602/4885ALDH1A1 4046/4885DAGLA 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.